Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 1, 2015, Pages 466-473

  Wang, Lijun ^a   Li, Juan ^b   Li, Dajun ^c  

^a Tianjin Hospital   (China)

^b Tianjin Medical Examination Service Tianjin Health Human Resources Service   (China)

^c FIRST TEACHING HOSPITAL OF TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Diabetes mellitus; Diabetic cardiomyopathy; JAK; Losartan; Myocardial interstitial fibrosis; STAT

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; JANUS KINASE; LOSARTAN; STAT PROTEIN;

ANIMAL; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; ENDOMYOCARDIAL FIBROSIS; HEART MUSCLE; MALE; METABOLISM; PATHOLOGY; RAT; SIGNAL TRANSDUCTION; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DIABETIC CARDIOMYOPATHIES; ENDOMYOCARDIAL FIBROSIS; JANUS KINASES; LOSARTAN; MALE; MYOCARDIUM; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84923099944     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. RS, JS, PZ, RT. Diabetes atlas 2003. 2nd edition. Brussels, Belgium: International Diabetes Federation; 2003.
2. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW and Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602.
3. Hayat SA, Patel B, Khattar RS and Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 2004; 107: 539-557.
4. Bell DS. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 1995; 18: 708-714.
5. Spector KS. Diabetic cardiomyopathy. Clin Cardiol 1998; 21: 885-887.
6. Watanabe K, Thandavarayan RA, Harima M, Sari FR, Gurusamy N, Veeraveedu PT, Mito S, Arozal W, Sukumaran V, Laksmanan AP, Soetikno V, Kodama M and Aizawa Y. Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy. Curr Cardiol Rev 2010; 6: 280-290.
7. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-791.
8. Kiu H and Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors 2012; 30: 88-106.
9. Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P and Bernstein KE. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 1995; 375: 247-250.
10. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G and Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 2008; 120: 172-185.
11. Srinivasan K, Viswanad B, Asrat L, Kaul CL and Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005; 52: 313-320.
12. G L. The answers to some quetions of the applications of insulin sensitivity index 1/(FPG × FINS). Chinese Journal of Diabetes 1998; 22: 44-48.
13. X C. Determination and evaluation of β-cell function and insulin resistance in type 2 diabetes. Chinese Journal of Microcirculation 2004; 26: 24-26.
14. Neuman RE and Logan MA. The determination of collagen and elastin in tissues. J Biol Chem 1950; 186: 549-556.
15. Bauters C, Lamblin N, Mc Fadden EP, Van Belle E, Millaire A and de Groote P. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2003; 2: 1.
16. Rodrigues B and McNeill JH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 1992; 26: 913-922.
17. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG and Bing OH. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 1995; 91: 161-170.
18. Solang L, Malmberg K and Ryden L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J 1999; 20: 789-795.
19. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A and Kajstura J. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest 2000; 80: 513-527.
20. Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME and Cao Z. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. Clin Sci (Lond) 2003; 104: 341-347.
21. Touyz RM and Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52: 639-672.
22. Shi Y and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
23. Li JH, Huang XR, Zhu HJ, Johnson R and Lan HY. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int 2003; 63: 2010-2019.
24. Campbell SE and Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 1997; 29: 1947-1958.
25. Yang F, Chung AC, Huang XR and Lan HY. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension 2009; 54: 877-884.
26. Mascareno E and Siddiqui MA. The role of Jak/STAT signaling in heart tissue renin-angiotensin system. Mol Cell Biochem 2000; 212: 171-175.